bioshares reports that commercialisation forges ahead stating that acrux looks like one of the biotechs success stories with $34 million in the bank and profitability in sight.the evamist project is going very well and that the company has many approaches for ellavie(evamistin usa)in europe,japan,korea,south africa and canada.ellavie will be distributed in australia by aspen pharmacare.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.524M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 68355 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 264830 | 2 |
View Market Depth
| Last trade - 10.00am 27/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable